Mitoxantrone-melphalan conditioning regimen for autologous stem cell transplantation in relapsed/refractory lymphoma

Creative Commons License

OKAY M., BÜYÜKAŞIK Y., DEMİROĞLU H., Malkan Ü. Y., Ciftciler R., ALADAĞ KARAKULAK E., ...More

TURKISH JOURNAL OF MEDICAL SCIENCES, vol.49, no.4, pp.985-992, 2019 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 49 Issue: 4
  • Publication Date: 2019
  • Doi Number: 10.3906/sag-1809-36
  • Journal Name: TURKISH JOURNAL OF MEDICAL SCIENCES
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.985-992
  • Keywords: Lymphoma, relapsed, autologous stem cell transplantation, HIGH-DOSE THERAPY, BONE-MARROW-TRANSPLANTATION, NON-HODGKIN-LYMPHOMA, SEQUENTIAL CHEMOTHERAPY, BEAM, INTENSIFICATION, CYTARABINE, ETOPOSIDE, BUSULFAN, DISEASE
  • Hacettepe University Affiliated: Yes

Abstract

Background/aim: High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) has become the standard approach for patients with relapsed/refractory Hodgkin's lymphoma (HL) or non-Hodgkin's lymphoma (NHL). In this study, we report the outcome of the mitoxantrone-melphalan conditioning regimen for lymphoma.